Search clinical trials for: Melanoma; unresectable; Interferon-alfa1b; Toripalimab; Anlotinib

Total 408 results

Shanghai Chest Hospital
Novartis; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; BeiGene

Not yet recruiting

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

KRAS Mutation-Related Tumors | Advanced Lung Cancer | Refractory Tumor

China
Taizhou Hospital

Not yet recruiting

Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell (SCLC)

SCLC | Maintenance Treatment
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors

Osteosarcoma | Other Solid Tumors

China
Sun Yat-sen University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

First-line Anlotinib Combined With Penpulimab for Advanced Pheochromocytoma: A Single-arm, Multicenter, Prospective Phase II Study

Pheochromocytoma

China
Peking University People's Hospital
Akeso Pharmaceuticals, Inc.

Not yet recruiting

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Locally Advanced Esophageal Squamous Cell Carcinoma
Fujian Cancer Hospital

Not yet recruiting

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Immunotherapy Gastroesophageal Junction

China
Ji Yongling

Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer
The First Affiliated Hospital, Guangzhou University...

Not yet recruiting

A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy

Advanced NSCLC
Army Medical Center of PLA

Recruiting

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

Neoadjuvant Therapy | Esophageal Squamous Cell Carcinoma

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

To Evaluate the Efficacy and Safety of Anrotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer

Event-free Lifetime

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Anlotinib Combined With Penpulimab as Front-line Treatment in Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
The First Hospital of Jilin University

Recruiting

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

Breast Cancer

China
Fudan University

Not yet recruiting

Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer

Breast Cancer

China
Hunan Cancer Hospital

Not yet recruiting

Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure

Melanoma
Guangzhou University of Traditional Chinese Medicine
Akeso Pharmaceuticals, Inc.

Recruiting

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Non-small Cell Lung Cancer

China
Fudan University

Not yet recruiting

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Small Cell Lung Cancer Recurrent

China
Pengyuan Liu

Recruiting

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)

China
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Ningbo No.2 Hospital

Not yet recruiting

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY)

Carcinoma, Non-Small-Cell Lung
Fudan University

Recruiting

Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma

Kidney Cancer | Renal Cell Carcinoma | Renal Clear Cell Carcinoma

China
Fudan University
Shanxi Province Cancer Hospital; Inner Mongolia Cancer Hospital Affiliated...

Recruiting

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Advanced Thyroid Cancer Patients Who Received Target Therapy

China
Ningbo Medical Center Lihuili Hospital

Recruiting

The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study

Non-Small Cell Lung Cancer

China
Shanghai Zhongshan Hospital

Not yet recruiting

A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer (WUKONG-9)

NSCLC
Tianjin Medical University Cancer Institute and...

Recruiting

Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
Kunming Medical University

Recruiting

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

China
Zhejiang Cancer Hospital

Recruiting

A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma Refractory

China
Peking Union Medical College Hospital

Not yet recruiting

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer (RCT-PAAG)

Pancreatic Adenocarcinoma Metastatic

China
Qianfoshan Hospital

Recruiting

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Advanced Non-small Cell Lung Cancer

China
Degan Lu
Wu Jieping Medical Foundation

Not yet recruiting

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Lung Cancer | Anlotinib | TKI Resistance | EGFR Sensitive Mutation | Pianzumab
Sichuan University

Not yet recruiting

Gemox Combined With Anlotinib and Sintilimab in Advanced cHCC-ICC

Combined Hepatocellular Cholangiocarcinoma
Shanghai Zhongshan Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib and TQB2450 in Advanced Hepatocellular Carcinoma After Failure of Prior Immune Checkpoint Inhibitors (FAITH)

Hepatocellular Carcinoma

China
Yan Xue

Recruiting

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

Breast Cancer

China
Peking Union Medical College Hospital

Recruiting

Prediction and Evaluation of Anlotinib Treatment Response Using Contrast Enhanced Ultrasound PPGL Patients

Ultrasonography | Pheochromocytoma, Metastatic | Paraganglioma, Malignant | Pheochromocytoma Malignant

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Colorectal Cancer

China
Qilu Hospital of Shandong University

Not yet recruiting

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Breast Cancer
Nanfang Hospital, Southern Medical University

Not yet recruiting

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

Neoadjuvant Therapy | Esophageal Carcinoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Thyroid Neoplasms

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Cadonilimab/Anlotinib in Locally Advanced or Relapsed/Metastatic ESCC Patients After Failure of PD-1 Combined With Platinum-containing Chemotherapy

Esophageal Squamous Cell Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Advanced Hepatocellular Carcinoma

China
Jinming Yu

Recruiting

A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy

Limited Stage Small Cell Lung Cancer | Not Progressed After First-line Chemoradiotherapy

China
RemeGen Co., Ltd.

Recruiting

RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

Solid Tumor

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment

Soft Tissue Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Zhejiang Cancer Hospital

Recruiting

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

Extensive Stage Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL

Pheochromocytoma | Paraganglioma

China
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Beijing Biostar Pharmaceuticals...

Recruiting

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

Esophageal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China

3

Subscribe